Otonomy Seen Rallying Up To 95% On Positive Meniere's Disease Data
Tuesday, August 15, 2017 11:40 AM EDT
JPMorgan this morning upgraded Otonomy (OTIC) to Overweight from Neutral, saying that the stock could rise up to 95% if the results of an upcoming trial of its Otividex drug are positive.
In this article: OTIC